In the field of targeted therapies for malignant tumors, the advent of ripretinib (QINLOCK) has brought renewed hope to patients with gastrointestinal stromal tumors (GIST). In particular, it provides a critical treatment option for patients whose disease continues to progress after multiple lines of therapy.
As a broad-spectrum kinase inhibitor with a novel and innovative mechanism of action,...
Italiano 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Greek